{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T06:38:45Z","timestamp":1722839925767},"publisher-location":"Chichester, UK","reference-count":33,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd010483.pub2","type":"reference-entry","created":{"date-parts":[[2013,11,19]],"date-time":"2013-11-19T15:03:47Z","timestamp":1384873427000},"source":"Crossref","is-referenced-by-count":8,"title":["Antiepileptic drugs for the treatment of severe myoclonic epilepsy in infancy"],"prefix":"10.1002","author":[{"given":"Francesco","family":"Brigo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Storti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,11,19]]},"reference":[{"issue":"9242","key":"10.1002\/14651858.CD010483.pub2-BIB1|cit1","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(00)03157-3","article-title":"Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO Study Group","volume":"356","author":"Chiron","year":"2000","journal-title":"Lancet"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD010483.pub2-BIB2|cit2","first-page":"155","article-title":"Stiripentol in severe myoclonic epilepsy in infancy (SMEI): a placebo-controlled Italian trial","volume":"43","author":"Guerrini","year":"2002","journal-title":"Epilepsia"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD010483.pub2-BIB3|cit3","first-page":"180","article-title":"Stiripentol in severe myoclonic epilepsy in infancy (SMEI): a placebo-controlled trial [abstract]","volume":"40","author":"Chiron","year":"1999","journal-title":"Epilepsia"},{"issue":"Suppl 7","key":"10.1002\/14651858.CD010483.pub2-BIB4|cit4","first-page":"159","article-title":"Stiripentol in severe myoclonic epilepsy in infancy (SMEI): a placebo-controlled trial [abstract]","volume":"40","author":"Chiron","year":"1999","journal-title":"Epilepsia"},{"issue":"1","key":"10.1002\/14651858.CD010483.pub2-BIB5|cit5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0920-1211(02)00010-4","article-title":"Topiramate as add-on drug in severe myoclonic epilepsy in infancy: an Italian multicenter open trial","volume":"49","author":"Coppola","year":"2002","journal-title":"Epilepsy Research"},{"key":"10.1002\/14651858.CD010483.pub2-BIB6|cit6","unstructured":"JPRN-JapicCTI-101116 Open phase III study of ME2080 in patients with Dravet syndrome, 2010 http:\/\/www.clinicaltrials.jp\/user\/showCteDetailE.jsp?japicId=JapicCTI-101116 (accessed 20th May 2013)"},{"key":"10.1002\/14651858.CD010483.pub2-BIB7|cit7","unstructured":"JPRN-JMA-IIA00014 Clinical evaluation of stiripentol in Dravet syndrome, 2007 https:\/\/dbcentre3.jmacct.med.or.jp\/jmactr\/App\/JMACTRE02_04\/JMACTRE02_04.aspx?kbn=3&seqno=382 (accessed 20th May 2013)"},{"issue":"2","key":"10.1002\/14651858.CD010483.pub2-BIB8|cit8","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1528-1167.2007.01423.x","article-title":"Severe myoclonic epilepsy in infancy: a systematic review and a meta-analysis of individual patient data","volume":"49","author":"Kassai","year":"2008","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD010483.pub2-BIB9|cit9","unstructured":"NCT01533506 Compassionate use of stiripentol in intractable epilepsy due to Dravet syndrome, 2012 http:\/\/clinicaltrials.gov\/show\/NCT01533506 (accessed 20th May 2013)"},{"key":"10.1002\/14651858.CD010483.pub2-BIB10|cit10","unstructured":"NCT01607073 Verapamil as adjunctive seizure therapy for children and young adults with Dravet syndrome, 2012 http:\/\/clinicaltrials.gov\/show\/NCT01607073 (accessed 20th May 2013)"},{"issue":"11","key":"10.1002\/14651858.CD010483.pub2-BIB11|cit11","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/S0929-693X(02)00090-8","article-title":"Long term efficacy and tolerance of stiripentol in severe myoclonic epilepsy of infancy (Dravet's syndrome)","volume":"9","author":"Nguyen Thanh","year":"2002","journal-title":"Archives de Pediatrie"},{"issue":"6","key":"10.1002\/14651858.CD010483.pub2-BIB12|cit12","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1111\/j.1528-1157.1994.tb01780.x","article-title":"Treatment of severe myoclonic epilepsy in infants with bromide and its borderline variant","volume":"35","author":"Oguni","year":"1994","journal-title":"Epilepsia"},{"issue":"3","key":"10.1002\/14651858.CD010483.pub2-BIB13|cit13","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/01.wnl.0000265222.24102.db","article-title":"An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy","volume":"69","author":"Striano","year":"2007","journal-title":"Neurology"},{"issue":"11","key":"10.1002\/14651858.CD010483.pub2-BIB14|cit14","first-page":"1120","article-title":"Long-term efficacy and tolerance of stiripentol in severe myoclonic epilepsy of infancy (Dravet's syndrome)","volume":"9","author":"ThanhTN","year":"2002","journal-title":"Archives de Pediatrie"},{"key":"10.1002\/14651858.CD010483.pub2-BIB15|cit15","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1517\/13543784.14.7.905","article-title":"Stiripentol","volume":"14","author":"Chiron","year":"2005","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1002\/14651858.CD010483.pub2-BIB16|cit16","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.nurt.2006.10.001","article-title":"Stiripentol","volume":"4","author":"Chiron","year":"2007","journal-title":"Neurotherapeutics"},{"issue":"3","key":"10.1002\/14651858.CD010483.pub2-BIB17|cit17","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s40263-012-0035-9","article-title":"A revisited strategy for antiepileptic drug development in children: designing an initial exploratory step","volume":"27","author":"Chiron","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1002\/14651858.CD010483.pub2-BIB18|cit18","first-page":"71","article-title":"Severe myoclonic epilepsy in infancy: Dravet syndrome","volume":"95","author":"Dravet","year":"2005","journal-title":"Advances in Neurology"},{"key":"10.1002\/14651858.CD010483.pub2-BIB19|cit19","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.neuropharm.2008.06.004","article-title":"The anti-convulsant stiripentol acts directly on the GABA(A) receptor as a positive allosteric modulator","volume":"56","author":"Fisher","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1002\/14651858.CD010483.pub2-BIB20|cit20","doi-asserted-by":"crossref","first-page":"531-46","DOI":"10.1093\/brain\/awg053","article-title":"Mutations of sodium channel alpha subunit type 1(SCN1A) in intractable childhood epilepsies with frequent generalized tonic-clonic seizures","volume":"126","author":"Fujiwara","year":"2003","journal-title":"Brain"},{"key":"10.1002\/14651858.CD010483.pub2-BIB21|cit21","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1124\/dmd.105.007237","article-title":"In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism","volume":"34","author":"Giraud","year":"2006","journal-title":"Drug Metabolism and Disposition"},{"key":"10.1002\/14651858.CD010483.pub2-BIB22|cit22","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD010483.pub2-BIB23|cit23","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]","author":"Higgins","year":"2011"},{"key":"10.1002\/14651858.CD010483.pub2-BIB24|cit24","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1528-1157.1990.tb05494.x","article-title":"Epidemiology of severe myoclonic epilepsy in infancy","volume":"31","author":"Hurst","year":"1990","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD010483.pub2-BIB25|cit25","first-page":"289","article-title":"Proposal for revised classification of epilepsies and epileptic syndromes","volume":"30","year":"1989","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD010483.pub2-BIB26|cit26","doi-asserted-by":"crossref","first-page":"c356","DOI":"10.1136\/bmj.c365","article-title":"impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews","volume":"340","author":"Kirkham","year":"2010","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD010483.pub2-BIB27|cit27","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD010483.pub2-BIB28|cit28","unstructured":"Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD010483.pub2-BIB29|cit29","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1212\/01.WNL.0000069463.41870.2F","article-title":"Spectrum of SCN1A mutations in severe myoclonic epilepsy of infancy","volume":"60","author":"Nabbout","year":"2003","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD010483.pub2-BIB30|cit30","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1111\/j.1528-1157.1999.tb02048.x","article-title":"Stiripentol: efficacy and tolerability in children with epilepsy","volume":"40","author":"Perez","year":"1999","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD010483.pub2-BIB31|cit31","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/j.1528-1167.2006.00497.x","article-title":"Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABA-A receptor channels","volume":"47","author":"Quilichini","year":"2006","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD010483.pub2-BIB32|cit32","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0387-7604(12)80147-1","article-title":"Early diagnosis of severe myoclonic epilepsy in infancy","volume":"14","author":"Yakoub","year":"1992","journal-title":"Brain and Development"},{"issue":"4","key":"10.1002\/14651858.CD010483.pub2-BIB33|cit33","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD010483.pub2","article-title":"Antiepileptic drugs for the treatment of severe myoclonic epilepsy in infancy","author":"Brigo","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"deposited":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T07:55:17Z","timestamp":1625039717000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/14651858.CD010483.pub2"}},"subtitle":[],"editor":[{"given":"Francesco","family":"Brigo","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,11,19]]},"references-count":33,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010483.pub2","relation":{},"subject":[],"published":{"date-parts":[[2013,11,19]]}}}